Aurora Cannabis (NASDAQ:ACB) Lowered to “Sell” Rating by Wall Street Zen

Aurora Cannabis (NASDAQ:ACB) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

Aurora Cannabis Price Performance

Shares of NASDAQ ACB opened at $4.15 on Friday. The company has a quick ratio of 2.16, a current ratio of 4.31 and a debt-to-equity ratio of 0.13. Aurora Cannabis has a 52 week low of $3.42 and a 52 week high of $7.20. The business’s 50 day moving average price is $5.03 and its 200 day moving average price is $4.73. The firm has a market cap of $233.27 million, a P/E ratio of 37.73 and a beta of 1.82.

Aurora Cannabis (NASDAQ:ACB) last released its quarterly earnings data on Wednesday, June 18th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.04). Aurora Cannabis had a return on equity of 0.13% and a net margin of 1.32%. The company had revenue of $63.34 million during the quarter, compared to analysts’ expectations of $88.85 million. On average, sell-side analysts expect that Aurora Cannabis will post 0.46 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. SBI Securities Co. Ltd. purchased a new position in shares of Aurora Cannabis during the 4th quarter valued at approximately $31,000. Susquehanna Fundamental Investments LLC acquired a new position in Aurora Cannabis in the 4th quarter valued at $45,000. JW Asset Management LLC acquired a new stake in shares of Aurora Cannabis in the 1st quarter worth $58,000. Cobblestone Asset Management LLC acquired a new stake in shares of Aurora Cannabis in the 1st quarter worth $67,000. Finally, Millennium Management LLC acquired a new stake in shares of Aurora Cannabis in the 4th quarter worth $67,000. Hedge funds and other institutional investors own 47.63% of the company’s stock.

About Aurora Cannabis

Aurora Cannabis Inc, together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada.